To explore the chromosomal abnormality rate of the blastocysts of patients with previous chromosome abnormality miscarriage (PCAM) undergoing preimplantation genetic testing for aneuploidies (PGT-A), and investigate the factors affecting the blastocyst abnormal rate.

In this retrospective study, the incidence of chromosomal abnormality in the blastocysts from patients undergoing PGT-A with PCAM were compared to the single gene defect patient with PGT-A (control). The relationship between parental age, basal follicle-stimulating hormone (FSH), FSH/luteinizing hormone (LH), body mass index (BMI), the frequency of spontaneous abortions, No. of cycles, M_II egg rate, fertilization rate, blastocyst formation rate, the biopsy blastocyst count, the presence of PCAM and the chromosomal abnormality rate of blastocyst were also analyzed by multiple linear regression analysis.

Multivariate linear regression analysis showed that female age and the presence of PCAM affected the rate of chromosomal abnormalities in biopsies. The chromosomal abnormality rate of blastocyst in PCMA group and control group were 25.29%, 27.42%, 45.76% and 18.22%, 19.85%, 31.55% (P=0.034, P=0.044, P=0.011) for women aged≤30 years, 31-34 years and 35-38 years respectively. For women aged >38 years, the chromosomal abnormality rate in PCMA group and control group were 63.64% and 46.15% (P=0.227).

>38-year-old PCAM patients have a high rate (over 60%) of chromosomal abnormalityin blastocysts and PGT-A treatment should be recommend to reduce the risk of next miscarriage caused by fetal chromosomal abnormalities. The chromosomal abnormalities of blastocysts in 35-38-year-old patients with PCAM were significantly higher than those in the control group. PGT-A treatment may be considered.

Spontaneous abortion; Embryo; Chromosome; Blastocyst; Preimplantation genetic testing for aneuploidies (PGT-A)